Skip to main content
Erschienen in: Clinical and Experimental Medicine 2/2019

15.03.2019 | Case Report

1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia

verfasst von: Giulia Daniele, Alberto L’Abbate, Antonella Turchiano, Orazio Palumbo, Massimo Carella, Crocifissa Lo Cunsolo, Paolo Iuzzolino, Angelo Lonoce, María Hernández-Sánchez, Carla Minoia, Patrizia Leone, Jesus Maria Hernandez-Rivas, Clelia Tiziana Storlazzi

Erschienen in: Clinical and Experimental Medicine | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

The identification of chromosome 1 translocations and deletions is a rare and poorly investigated event in chronic lymphocytic leukemia (CLL). Nevertheless, the identification of novel additional molecular alterations is of great interest, opening to new prognostic and therapeutic strategies for such heterogeneous hematological disease. We here describe a patient affected by CLL with a mutated IGHV status, showing a balanced t(1;3)(q23.1;q21.3) translocation and a der(18)t(1;18)(q24.2;p11.32), accompanying the recurrent 13q14 heterozygous deletion in all analyzed cells at onset. By combining whole-genome sequencing, SNP array, RNA sequencing, and FISH analyses, we defined a 1q23.1 biallelic minimally deleted region flanking translocations breakpoints at both derivative chromosome 1 homologues. The deletion resulted in the downregulation of the Fc receptor-like family genes FCRL1, FCRL2, and FCRL3 and in the lack of expression of FCRL5, observed by RT-qPCR. The mutational status of TP53, NOTCH1, SF3B1, MYD88, FBXW7, and XPO1 was investigated by targeted next-generation sequencing, detecting a frameshift deletion within NOTCH1 (c.7544_7545delCT). We hypothesize a loss of tumor suppressor function for FCRL genes, cooperating with NOTCH1 mutation and 13q14 genomic loss in our patient, both conferring a negative prognosis, independently from the known biological prognostic factors of CLL.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat ISCN 2016. An international system for human cytogenomic nomenclature (2016) McGowan-Jordan J, Simons A, Schmid M (eds), Karger, Basel. ISCN 2016. An international system for human cytogenomic nomenclature (2016) McGowan-Jordan J, Simons A, Schmid M (eds), Karger, Basel.
23.
Zurück zum Zitat Zheng Z, Venkatapathy S, Rao G, Harrington CA. Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia. 2002;16(12):2429–37. https://doi.org/10.1038/sj.leu.2402711.CrossRefPubMed Zheng Z, Venkatapathy S, Rao G, Harrington CA. Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia. 2002;16(12):2429–37. https://​doi.​org/​10.​1038/​sj.​leu.​2402711.CrossRefPubMed
Metadaten
Titel
1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia
verfasst von
Giulia Daniele
Alberto L’Abbate
Antonella Turchiano
Orazio Palumbo
Massimo Carella
Crocifissa Lo Cunsolo
Paolo Iuzzolino
Angelo Lonoce
María Hernández-Sánchez
Carla Minoia
Patrizia Leone
Jesus Maria Hernandez-Rivas
Clelia Tiziana Storlazzi
Publikationsdatum
15.03.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 2/2019
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-019-00551-0

Weitere Artikel der Ausgabe 2/2019

Clinical and Experimental Medicine 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.